Prostate Cancer | Specialty

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Apalutamide Linked to OS Benefit in Nonmetastatic CRPC

September 27th 2019

The next-generation androgen receptor apalutamide, in combination with androgen deprivation therapy, demonstrated a 25% reduction in the risk of death compared with placebo/ADT in patients with nonmetastatic castration-resistant prostate cancer in the phase III SPARTAN trial.

Dr. Henderson on Accessibility of Proton Therapy in Prostate Cancer

September 25th 2019

Randal H. Henderson, MD, MBA, discusses accessibility of proton therapy versus intensity-modulated radiation therapy in prostate cancer.

Dr. Kohli on the Challenges of Molecular Classification in Prostate Cancer

September 25th 2019

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

The Prostate Cancer Paradox Revisited

September 25th 2019

Conflicting guidelines on prostate-specific antigen testing have affected trends on disease presentation and, potentially, the treatment outcomes for many men with this disease. New agents and powerful new imaging tools have added yet more complexity to the decision process. Therefore, more investigation and cooperation on multiple levels is needed to define appropriate standards of care.

Genetic Testing Gaining Larger Role in Prostate Cancer

September 18th 2019

Leonard G. Gomella, MD, FACS, discusses the role of genetic testing and emerging biomarkers in prostate cancer.

FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

September 18th 2019

The FDA has approved apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

Dr. George on the Use of Radium-223 in Prostate Cancer

September 18th 2019

Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the use of radium-223 dichloride (Xofigo) in prostate cancer.

Carboplatin/Cabazitaxel Combo Shows PFS Benefit in mCRPC

September 17th 2019

The combination of cabazitaxel in combination with carboplatin demonstrated an improvement in progression-free survival versus cabazitaxel alone in men with metastatic castration-resistant prostate cancer.

Search for New Prostate Cancer Targets Yields a Profusion of Options

September 11th 2019

Despite the introduction of novel therapies over the past decade, advanced prostate cancer remains an incurable disease in need of new strategies to overcome drug resistance.

Dr. Kohli Discusses Ongoing Correlative Science in Prostate Cancer

September 11th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses ongoing research with correlative sciences in prostate cancer.

Dr. Davis on the ANZUP Collaboration on the ENZAMET Trial in Prostate Cancer

September 10th 2019

Ian Davis, MBBS, PhD, FRACP, FAChPM, professor of medicine at Monash University and Eastern Health, and head of the Eastern Health Clinical School, discusses the Australian and New Zealand Urogenital and Prostate Cancer Trials Group collaboration on the randomizedphase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

Dr. Henderson on Anticipated Developments With Radiotherapy in Prostate Cancer

September 10th 2019

Randal H. Henderson, MD, MBA, professor, Department of Radiation Oncology, associate medical director, University of Florida Health Proton Therapy Institute, discusses anticipated developments with radiotherapy in prostate cancer.

Real-World Data With Sipuleucel-T Showcase Promising OS in mCRPC

September 5th 2019

Sipuleucel-T (Provenge) was associated with a median overall survival of 47.7 months in a subgroup of patients with asymptomatic or minimally invasive metastatic castration-resistant prostate cancer.

Dr. Jain on Radioligand Therapy in Prostate Cancer

September 5th 2019

Manoj K. Jain, MD, discusses the use of radioligand therapy in prostate cancer.

Dr. Kohli on Sequencing Concerns in Metastatic Hormone-Sensitive Prostate Cancer

September 4th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).

Tracers Increase PET Imaging Sensitivity in Prostate Cancer

August 27th 2019

Manoj K. Jain, MD, discusses new imaging modalities and what they could mean for the field going forward.